Live Breaking News & Updates on Hybrid Congress

Stay updated with breaking news from Hybrid congress. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress

More than 20 abstracts will be presented from clinical trials and real-world evidence using clonoSEQ for MRD assessment across multiple types of blood cancersSEATTLE, May 31, 2024 Adaptive. ....

Spain , Madrid , Chicago , Illinois , United-states , University-of-chicago , American , Ciltacabtagene-autoleucel , Susan-bobulsky , Lisocabtagene-maraleucel , Obecabtagene-autoleucel , Brexucabtagene-autoleucel-brexu

Adaptive Biotechnologies Announces Data Supporting the

Adaptive Biotechnologies Announces Data Supporting the
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

Madrid , Spain , University-of-chicago , Illinois , United-states , Chicago , American , Idecabtagene-vicleucel-ide , Erica-jones , Susan-bobulsky , Vendexv-pomalidomide , Obecabtagene-autoleucel

Samsung Bioepis to Present Post-hoc Analysis of Phase 3

Post-hoc analysis of Phase 3 study to highlight transfusion avoidance results of SB12 compared to reference eculizumab-treated groups INCHEON, Korea, May . ....

Spain , Madrid , Eculizumab-biosimilar , Younsoo-kim , Samsung-bioepis , Jihyun-han , Paola-russo , Hyejin-kim , Hus-laboratory-monitoring , Lifecycle-safety-team-leader-at-samsung-bioepis , Linkedin , European-hematology-association

Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)

Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Cambridge , Cambridgeshire , United-kingdom , Becker-hewes , Mastocytosis-adv , Twitter , European-hematology-association , Blueprint-medicines-corporation , European-academy-of-allergy , Prnewswire-blueprint-medicines-corporation-nasdaq , Linkedin , European-commission

HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress

HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

Spain , Ying-qian , Jiangxi , China , Madrid , Tianjin , Texas , United-states , Shanghai , Wuhan , Hubei , Norway